Journal of Gastrointestinal & Digestive System

Miqdady, J Gastrointest Dig Syst 2019, 9:4 ISSN: 2161-069X

Market Analysis Open Access

Market Analysis on Gastroenterology and Hepatology

Mohammad Miqdady

Sheikh Khalifa Medical City, Abu Dhabi, UAE E-mail: msmiqdadi@yahoo.com

Gastroenterology is a medical specialty focusing on the structure, function, pathology and disorders of the gastrointestinal system. Diseases which affect the gastrointestinal tract, i.e., organs from mouth to anus, along the alimentary canal, are the focus of this specialty.


The market for gastrointestinal pharmaceuticals is divided into two general segments: prescription gastrointestinal pharmaceuticals and OTC gastrointestinal pharmaceuticals. Similarly, the market for gastrointestinal diagnostics, testing and vaccines is divided into three general segments: Diagnostics and testing market, Medical devices (endoscopy), Vaccines.

The size of the global gastrointestinal therapeutics market is expected to reach USD 13.8 billion by 2020, accelerating at a CAGR of 6.5% between 2015-2020. This growth in market size is attributed to numerous factors including increasing consumption of biologics, tentative approval of late stage molecules, development of novel therapies using innovative technologies, and improved diagnostic tools increasing the treatment-seeking population.

Additionally, a sudden increase in the number of gastric surgeries across the globe is directly impacting the growth of post-surgical gastro paresis cases across the globe, which will directly propel growth within the gastro paresis drugs market over the next few years. Due to this primary growth factor, the global gastro paresis drugs market will increase USD 940 million between 2016-2021, exceeding USD 7.1 billion in market size by the end of the forecast period. Other factors driving the growth of this market include unmet needs in the industry to increase the R&D in the field and the

rising cases of diabetes fueling the prevalence of diabetic gastroparesis.

The expanding consumption of biologics for inflammatory bowel diseases (IBD) is one of the factors that are having a positive impact on the growth of gastrointestinal therapeutics market size in the upcoming years. The global gastro paresis drugs market is expected to accelerate at a CAGR of 3% during 2017-2021. Fast track approvals and acquisitions to change the phase of the market and the introduction of novel ways for the treatment of gastro paresis symptoms are the emerging trends which will gain traction during the forecast period. These trends will positively impact the market's growth.



The global gastrointestinal endoscopic devices market accounted for approximately USD 5.6 Billion in 2015 and is expected to reach approximately USD 8.5 Billion by 2021, growing at a CAGR of around 7.0% between 2016 and 2021.

The global market for gastrointestinal disorder therapeutics and diagnostics reached \$49.6 billion in 2015. This market is expected to grow from nearly

\$51.8 billion in 2016 to \$63.8 billion in 2021 at a compound annual growth rate of 4.3% from 2016-


2021. According to Market research the Global Gastrointestinal Drugs Market Revenue by Region in 2016, North America was the highest by getting the revenue of 17,288 US Dollar Million, while the Middle East and Africa Continent was having least generation of revenue.

The prescription therapies market is expected to grow from \$18.6 billion in 2016 to nearly \$22.1 billion in 2021 at a CAGR of 3.5% for the period 2016-2021. The diagnostics market over the next five years will grow from \$17.7 billion in 2016 to \$23.5 billion in 2021 at a CAGR of 5.9% for the period 2016-2021.

The demand for ambulatory surgery center is high in Europe and Asia Pacific owing to the government initiatives to overcome the shortage of medical facilities in remote areas of developing countries such as India and China. The North America ambulatory surgery center market is expected to witness significant growth rate in future due to the enough outpatient surgery centers and government regulations governing the preference for outpatient surgery centers in order to expand the reach of medical facilities.

During the forecast period, the growing inclination for minimally invasive (MI) procedures is expected to drive the development prospects for the global gastrointestinal stents market. Generally, MI surgeries have low-risk complications and other benefits such as reduced incision marks, bleeding control, minimal complications, reduced costs, shorter hospital stay, faster recovery, lesser pain, fewer post-surgery infections, and heightened accuracy. New Technological advancements will continue to precede the gastrointestinal endoscope market. Recent generations of endoscopes will continue to progressively promote on visualization and detection technologies. It is projected to exceed \$1.7 billion by 2020.





In the United States, 20 per cent to 30 per cent of individuals living with HIV are co-infected with HCV. Hepatitis C is common among individuals living with HIV. This implies that approximately 225,000 to 330,000 individuals in the United States are living with both viruses. The larger part of individuals living with hepatitis C does not know they have it. The most common course of transmission in the UK is utilizing non-sterile needles and other equipment for infusing drugs. 90 per cent of individuals who got HIV from infusing drugs are moreover infected with HCV. This is since both infections can be spread effectively through blood and blood products.

The Main aim of the market research is to increase the awareness of gastrointestinal disorders among people and to identify the gastrointestinal market landscape as well as important advancements. With the support of our organizing committee members, Dr. Mohammad Miqdady, Sheikh Khalifa City, UAE we take the privilege in scheduling the upcoming event "20th International Conference on Gastroenterology and Hepatology" which is going to be held during September 24-25, 2020 in Abu Dhabi, UAE.

Anna Harper

Program Manager | World Gastro 2020 Email: gastrocongress@memeetings.com Phone No.: +1-201-380-5561; Extn. 7006 WhatsApp No.: +44 7723584386